A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis.

Trial Profile

A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms PURSUIT-Induction; PURSUIT-SC
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 05 Feb 2014 Results have been published in Gastroenterology according to a Janssen media release. Results were also reported in the media release.
    • 16 Oct 2013 Post-hoc analysis for the association between patient reported outcomes (stool frequency and rectal bleeding ) and mucosal healing presented at the 21st United European Gastroenterology Week.
    • 16 Oct 2013 Subgroup analysis results looking at the effect of immunomodulators on the pharmacokinetics and efficacy of golimumab presented at the 21st United European Gastroenterology Week.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top